Thursday, April 23, 2026

Hanskin enters 1,400 Ulta Beauty stores in U.S., expanding North American offline presence

Hanskin expands its North American presence by launching "Hyaluron Skin Essence" in 1,400 Ulta Beauty stores, enhancing brand visibility.

Hyundai’s Massive Driving Experience Center Kicks Off 2025 Season

Hyundai Motor Group launches the 2025 season of the HMG Driving Experience Center, featuring advanced driving courses and programs.

Tag: Lunit

Lunit’s AI-based bile duct cancer study selected for rapid oral presentation at U.S. oncology conference

Lunit will present five research abstracts at ASCO 2026, showcasing the expanding role of AI biomarkers in cancer treatment.

Lunit supplies integrated breast cancer diagnostic solution to Lexington Clinic

Lunit supplies integrated breast cancer AI solutions to Lexington Clinic, enhancing diagnostics and expanding its presence in the Americas.

Lunit’s 200 Billion KRW Funding: How Atinum Investment Boosts AI in Healthcare

Lunit secures 30 billion KRW investment from Atinum to enhance global R&D and operations, reinforcing its position in medical AI.

Lunit’s AI Innovations: How a Meeting with France’s SGPI Could Transform Healthcare

Lunit discusses collaboration with France's SGPI to enhance medical AI technology in public healthcare, aligning with a strategic partnership.

Lunit’s AI Foundation Model: Transforming Healthcare with 16 Billion Parameters

Medical AI firm Lunit successfully passes the first phase of a national project and enters the second phase of nationwide validation.

AI in Healthcare: How Lunit and KAIST Are Revolutionizing Medical Technology in 2026

South Korea enhances AI in healthcare with Lunit and KAIST's models, achieving high accuracy and speed for medical applications.

Lunit and Selcarta Join Forces: Accelerating AI Biomarker Companion Diagnostics in 2026

Lunit partners with Selcarta to enhance AI-based biomarkers for diagnostics, aiming to streamline clinical trials and accelerate drug development.

Lunit Scope: How AI Biomarkers Are Revolutionizing Cancer Treatment at AACR 2026

Lunit to present six AI biomarker studies at AACR 2026, showcasing advancements in cancer treatment and AI technology.

How Lunit’s AI is Transforming Early Breast Cancer Risk Assessment: Key Findings from ECR 2026

Lunit presents 21 research findings at ECR 2026, showcasing AI's potential in breast cancer risk assessment and screening innovations.

Top News

- Our Sponsors Ad -

Follow us